Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | GRM6 | O15303 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1352474 | 0.84 | DGAT1 (0.46) | DGAT1BCHEELANECA12CA1 | |
| SCHEMBL320271 | 0.78 | DGAT1 (0.50) | DGAT1BCHEELANECA1CA2 | |
| SCHEMBL11552854 | 0.78 | DGAT1 (0.50) | DGAT1BCHEMAPK1ELANENPC1 | |
| SCHEMBL161854 | 0.78 | DGAT1 (0.50) | DGAT1BCHEMAPK1ELANENPC1 | |
| SCHEMBL27747511 | 0.78 | DGAT1 (0.50) | DGAT1BCHEELANECA1CA2 | |
| SCHEMBL6687359 | 0.78 | DGAT1 (0.50) | DGAT1BCHEELANECA1CA2 | |
| SCHEMBL14606262 | 0.78 | DGAT1 (0.50) | DGAT1BCHEMAPK1ELANENPC1 | |
| Hydrochloric Acid SCHEMBL16632764 | 0.76 | DGAT1 (0.48) | DGAT1CA1CA2SMN1; SMN2 | |
| SCHEMBL10892362 | 0.76 | DGAT1 (0.48) | DGAT1CA1CA2SMN1; SMN2 | |
| SCHEMBL5870536 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240058458-A1 | METHODS, COMPOUNDS, AND COMPOSITIONS FOR MODIFYING CAR-T CELL ACTIVITY | PURDUE RESEARCH FOUNDATION (US) | 2024-02-22 | — | — | US | disclosed |
| US-10675354-B2 | Glycosaminoglycan derivative and method for producing same | SEIKAGAKU CORPORATION (JP) | 2020-06-09 | — | — | US | disclosed |
| US-20200155694-A1 | GLYCOSAMINOGLYCAN DERIVATIVE AND METHOD FOR PRODUCING SAME | SEIKAGAKU CORPORATION (JP) | 2020-05-21 | — | — | US | disclosed |
| US-20190184023-A1 | GLYCOSAMINOGLYCAN DERIVATIVE AND METHOD FOR PRODUCING SAME | SEIKAGAKU CORPORATION (JP) | 2019-06-20 | — | — | US | disclosed |
| CN-101921347-B | Hyaluronic acid derivative and drug containing the same | SEIKAGAKU KOGYO CO LTD | 2014-07-30 | — | — | CN | disclosed |
| CN-102079746-A | Pyrazolo-quinazoline derivatives,process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL | 2011-06-01 | — | — | CN | disclosed |
| CN-1930190-B | Hyaluronic acid derivative and drug containing same | SEIKAGAKU KOGYO CO LTD | 2011-04-20 | — | — | CN | disclosed |
| CN-101921347-A | Derivatives of hyaluronic acids and contain its medicament | SEIKAGAKU KOGYO CO LTD | 2010-12-22 | — | — | CN | disclosed |
| CN-1930190-A | Hyaluronic acid derivative and drug containing same | SEIKAGAKU KOGYO CO LTD (JP) | 2007-03-14 | — | — | CN | disclosed |
| CN-1293055-C | Piperidine derivative crystal, midbody for preparation and preparing method | AJINOMOTO KK (JP) | 2007-01-03 | — | — | CN | disclosed |
| CN-1826343-A | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | PHARMACIA ITALIA SPA (IT) | 2006-08-30 | — | — | CN | disclosed |
| CN-1515553-A | Piperidine derivative crystal, midbody for preparation and preparing method | ֮����ʽ���� | 2004-07-28 | — | — | CN | disclosed |
| CN-1121402-C | Crystal of piperidine derivative, intermediate for production thereof, and process for production thereof | AJINOMOTO KK (JP) | 2003-09-17 | — | — | CN | disclosed |
| CN-1151403-A | Crystal of piperidine derivative, intermediate for production thereof, and process for production thereof | AJINOMOTO KK (JP) | 1997-06-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240058458-A1 | METHODS, COMPOUNDS, AND COMPOSITIONS FOR MODIFYING CAR-T CELL ACTIVITY | ICOS, CD4, NFATC1 | DGAT1 397/4885BCHE 293/4885MAPK1 3056/4885 |
| US-20200155694-A1 | GLYCOSAMINOGLYCAN DERIVATIVE AND METHOD FOR PRODUCING SAME | CSGALNACT1, CD44, GUSB | DGAT1 1104/4885BCHE 807/4885MAPK1 4458/4885 |
| US-10675354-B2 | Glycosaminoglycan derivative and method for producing same | CSGALNACT1, CD44, GUSB | DGAT1 1104/4885BCHE 807/4885MAPK1 4458/4885 |
| US-20190184023-A1 | GLYCOSAMINOGLYCAN DERIVATIVE AND METHOD FOR PRODUCING SAME | CSGALNACT1, CD44, GUSB | DGAT1 1104/4885BCHE 807/4885MAPK1 4458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.